Stellus Capital shows poor earnings, weak dividend coverage, high non-accruals and limited growth with declining NAV. Learn ...
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
21h
SOLAI Limited Announces Unaudited Financial Results for the Three Months Ended September 30, 2025
SOLAI Limited (NYSE: SLAI) (previously traded under "BTCM") ("SOLAI," "the Company," "we," "us," or "our company"), a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback